Eliquis Gains Three New Indications

August 21, 2014 8:22 PM

20 0

The approval for the new indications was based on data from the global AMPLIFY and AMPLIFY-EXT studies. AMPLIFY was a randomized, double-blind trial that included patients with confirmed symptomatic DVT or PE (n=2609 [Eliquis] and n=2635 [standard of care]).

Results showed that Eliquis 10mg twice daily for one week followed by 5mg twice daily for six months showed effiacy comparable to standard of care in treating DVT/PE patients for the primary efficacy composite endpoint of recurrent, symptomatic VTE, or VTE-related death (2.3% vs. 2.7%, RR 0.84, 95% ...

Read more

To category page